Vanderbilt Heart and Vascular Institute now offers patients with atrial fibrillation (AF) an alternative treatment to reduce their risk of stroke, potentially avoiding the long-term use of blood thinners such as warfarin.

Two vastly different causes of heart failure, both of which can devastate a patient’s life, are being studied at Vanderbilt University Medical Center thanks, in part, to the generosity of a grateful patient whose own damaged heart was repaired at Vanderbilt more than five years ago.

Despite prior epidemiologic and experimental data to the contrary, new research shows that vitamin D supplementation does not reduce blood pressure in individuals with prehypertension or stage I hypertension and vitamin D deficiency.

Vanderbilt is embarking on an observational study to define and understand how a promising treatment for multiple myeloma affects the heart.

Carrie Romero of Columbia, Tennessee, is running for her life. In 1997, when she was 28, Romero was diagnosed with dilated cardiomyopathy — a heart muscle disease that puts her at risk for sudden cardiac arrest (SCA).

Vanderbilt Heart and Vascular Institute (VHVI) reached a significant milestone recently with the 100th implantation of the miniaturized HeartWare HVAD Pump, a left ventricular assist device (LVAD) that supports the heart.

Vanderbilt Heart and Vascular Institute (VHVI) recently hosted a cardiovascular health screening for participants in a nonprofit organization called the Enplay Foundation, for middle and high school athletes and their adult family members.